Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab.

Cataldo A, Piovan C, Plantamura I, D'Ippolito E, Camelliti S, Casalini P, Giussani M, Déas O, Cairo S, Judde JG, Tagliabue E, Iorio MV.

Oncotarget. 2018 Jun 15;9(46):27920-27928. doi: 10.18632/oncotarget.24723. eCollection 2018 Jun 15.

2.

The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, Tagliabue E, Campiglio M, Bianchi F.

BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9.

3.

Lipid accumulation in human breast cancer cells injured by iron depletors.

De Bortoli M, Taverna E, Maffioli E, Casalini P, Crisafi F, Kumar V, Caccia C, Polli D, Tedeschi G, Bongarzone I.

J Exp Clin Cancer Res. 2018 Apr 3;37(1):75. doi: 10.1186/s13046-018-0737-z.

4.

Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.

Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP.

Cancer Immunol Res. 2018 May;6(5):552-565. doi: 10.1158/2326-6066.CIR-17-0385. Epub 2018 Mar 9.

PMID:
29523597
5.

Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers.

Di Modica M, Regondi V, Sandri M, Iorio MV, Zanetti A, Tagliabue E, Casalini P, Triulzi T.

Cancer Lett. 2017 Jan 1;384:94-100. doi: 10.1016/j.canlet.2016.09.013. Epub 2016 Sep 28.

6.
7.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

8.

CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.

Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M.

Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935.

9.

miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer.

D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, De Braud F, Di Leva G, Tripodo C, Iorio MV.

Cancer Res. 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140. Epub 2016 Jul 11.

10.

Pulmonary scintigraphy as a method to investigate gastrobronchial communication in tracheostomized patients.

Graziani A, Martelli A, Quercia O, Spadazzi AP, Del Giudice E, Stefanini FG, Lanzi A, Casalini P, Pezzi G, Mirici Cappa F.

Respir Med Case Rep. 2015 Jun 20;16:29-31. doi: 10.1016/j.rmcr.2015.05.015. eCollection 2015.

11.

Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells.

Andriani F, Bertolini G, Facchinetti F, Baldoli E, Moro M, Casalini P, Caserini R, Milione M, Leone G, Pelosi G, Pastorino U, Sozzi G, Roz L.

Mol Oncol. 2016 Feb;10(2):253-71. doi: 10.1016/j.molonc.2015.10.002. Epub 2015 Oct 22.

12.

Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells.

Bianchi F, Sasso M, Turdo F, Beretta GL, Casalini P, Ghirelli C, Sfondrini L, Ménard S, Tagliabue E, Campiglio M.

J Cell Physiol. 2015 Nov;230(11):2661-70. doi: 10.1002/jcp.24968.

PMID:
25711523
13.

Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies.

Sangaletti S, Tripodo C, Portararo P, Dugo M, Vitali C, Botti L, Guarnotta C, Cappetti B, Gulino A, Torselli I, Casalini P, Chiodoni C, Colombo MP.

Oncoimmunology. 2014 Jun 5;3:e28989. eCollection 2014.

14.

miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.

Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, Pilotti S, Degl'Innocenti D, Lanzi C, Casalini P, Pierotti MA, Greco A, Borrello MG.

Oncotarget. 2014 May 15;5(9):2513-28.

15.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015. Epub 2014 Mar 27.

16.

Maspin influences response to doxorubicin by changing the tumor microenvironment organization.

Triulzi T, Ratti M, Tortoreto M, Ghirelli C, Aiello P, Regondi V, Di Modica M, Cominetti D, Carcangiu ML, Moliterni A, Balsari A, Casalini P, Tagliabue E.

Int J Cancer. 2014 Jun 15;134(12):2789-97. doi: 10.1002/ijc.28608. Epub 2013 Nov 30.

17.

Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma.

Sangaletti S, Tripodo C, Vitali C, Portararo P, Guarnotta C, Casalini P, Cappetti B, Miotti S, Pinciroli P, Fuligni F, Fais F, Piccaluga PP, Colombo MP.

Cancer Discov. 2014 Jan;4(1):110-29. doi: 10.1158/2159-8290.CD-13-0276. Epub 2013 Nov 4.

18.

Selective axillary dissection after axillary reverse mapping to prevent breast-cancer-related lymphoedema.

Gennaro M, Maccauro M, Sigari C, Casalini P, Bedodi L, Conti AR, Caraceni A, Bombardieri E.

Eur J Surg Oncol. 2013 Dec;39(12):1341-5. doi: 10.1016/j.ejso.2013.09.022. Epub 2013 Oct 3.

PMID:
24113621
19.

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.

Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E.

Breast Cancer Res Treat. 2013 Aug;141(1):101-10. doi: 10.1007/s10549-013-2658-z. Epub 2013 Aug 13.

20.

Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress.

Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu ML, Colombo MP, Balsari A, Ménard S, Orlandi R, Tagliabue E.

PLoS One. 2013;8(2):e56761. doi: 10.1371/journal.pone.0056761. Epub 2013 Feb 18.

21.

Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity.

Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, Piconese S, Parenza M, Guiducci C, Vitali C, Colombo MP.

Blood. 2012 Oct 11;120(15):3007-18. doi: 10.1182/blood-2012-03-416156. Epub 2012 Aug 29.

22.

Occurrence of breast cancer after chest wall irradiation for pediatric cancer, as detected by a multimodal screening program.

Terenziani M, Casalini P, Scaperrotta G, Gandola L, Trecate G, Catania S, Cefalo G, Conti A, Massimino M, Meazza C, Podda M, Spreafico F, Suman L, Gennaro M.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):35-9. doi: 10.1016/j.ijrobp.2012.03.043. Epub 2012 Jun 5.

PMID:
22677366
23.

FOXP3 expression in tumor cells and implications for cancer progression.

Triulzi T, Tagliabue E, Balsari A, Casalini P.

J Cell Physiol. 2013 Jan;228(1):30-5. doi: 10.1002/jcp.24125. Review.

PMID:
22674548
24.

Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM.

Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. Epub 2012 Apr 19.

25.

Breast cancer and microRNAs: therapeutic impact.

Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E.

Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1. Review.

PMID:
22015296
26.

SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.

Sangaletti S, Tripodo C, Cappetti B, Casalini P, Chiodoni C, Piconese S, Santangelo A, Parenza M, Arioli I, Miotti S, Colombo MP.

Am J Pathol. 2011 Dec;179(6):3000-10. doi: 10.1016/j.ajpath.2011.08.027. Epub 2011 Oct 11. Erratum in: Am J Pathol. 2012 Mar;180(3):1324.

27.

Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.

Nicolini V, Cassinelli G, Cuccuru G, Bongarzone I, Petrangolini G, Tortoreto M, Mondellini P, Casalini P, Favini E, Zaffaroni N, Zunino F, Lanzi C.

Biochem Pharmacol. 2011 Oct 1;82(7):778-88. doi: 10.1016/j.bcp.2011.06.037. Epub 2011 Jul 2.

PMID:
21741956
28.

Angiosarcoma of the breast and vascular endothelial growth factor receptor.

Gennaro M, Valeri B, Casalini P, Carcangiu ML, Gronchi A, Conti AR, Agresti R, Greco M.

Tumori. 2010 Nov-Dec;96(6):930-5.

PMID:
21388054
29.

Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.

Caccia D, Miccichè F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I.

Mol Cancer. 2010 Oct 18;9:278. doi: 10.1186/1476-4598-9-278.

30.

Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.

Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, Jocollè G, Cassinelli G, Grosso F, Sanfilippo R, Casalini P, Greco A, Pierotti MA, Pilotti S.

Clin Cancer Res. 2010 Jul 15;16(14):3581-93. doi: 10.1158/1078-0432.CCR-09-2912. Epub 2010 Jun 3.

31.

MicroRNAs and future therapeutic applications in cancer.

Casalini P, Iorio MV.

J BUON. 2009 Sep;14 Suppl 1:S17-22. Review.

PMID:
19785062
32.

Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity.

Appierto V, Tiberio P, Cavadini E, Casalini P, Cappelletti G, Formelli F.

Mol Cancer Ther. 2009 Dec;8(12):3360-8. doi: 10.1158/1535-7163.MCT-09-0798.

33.

Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.

Carcangiu ML, Radice P, Casalini P, Bertario L, Merola M, Sala P.

Int J Surg Pathol. 2010 Feb;18(1):21-6. doi: 10.1177/1066896909332117. Epub 2009 May 14.

PMID:
19443869
34.

microRNA-205 regulates HER3 in human breast cancer.

Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E.

Cancer Res. 2009 Mar 15;69(6):2195-200. doi: 10.1158/0008-5472.CAN-08-2920. Epub 2009 Mar 10.

35.

FOXP3 expression and overall survival in breast cancer.

Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Mènard S, Tagliabue E, Balsari A.

J Clin Oncol. 2009 Apr 10;27(11):1746-52. doi: 10.1200/JCO.2008.17.9036. Epub 2009 Mar 2.

PMID:
19255331
36.

MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer.

Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM.

Eur J Cancer. 2008 Dec;44(18):2753-9. doi: 10.1016/j.ejca.2008.09.037. Epub 2008 Nov 18. Review.

PMID:
19022662
37.

Biology, prognosis and response to therapy of breast carcinomas according to HER2 score.

Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandarà M, Mottolese M, Marandino F, Venturini M, Bighin C, Cancello G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, Battelli N, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G; OMERO Group.

Ann Oncol. 2008 Oct;19(10):1706-12. doi: 10.1093/annonc/mdn369. Epub 2008 Jun 9.

PMID:
18544559
38.

Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact.

Casalini P, Carcangiu ML, Tammi R, Auvinen P, Kosma VM, Valagussa P, Greco M, Balsari A, Ménard S, Tagliabue E.

Clin Cancer Res. 2008 Jan 1;14(1):25-31. doi: 10.1158/1078-0432.CCR-07-0450.

39.

Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, Misiano P, Farina C, Zunino F.

J Pharmacol Exp Ther. 2008 Jan;324(1):15-22. Epub 2007 Oct 1.

40.

Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.

Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D.

J Immunother. 2007 Oct;30(7):684-93.

PMID:
17893561
41.

MicroRNA signatures in human ovarian cancer.

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM.

Cancer Res. 2007 Sep 15;67(18):8699-707.

42.

Relationship between p53 and p27 expression following HER2 signaling.

Casalini P, Iorio MV, Berno V, Bergamaschi A, Børresen Dale AL, Gasparini P, Orlandi R, Casati B, Tagliabue E, Ménard S.

Breast. 2007 Dec;16(6):597-605. Epub 2007 Jun 28.

PMID:
17604627
43.

Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness.

Tagliabue E, Agresti R, Casalini P, Mariani L, Carcangiu ML, Balsari A, Veronesi U, Ménard S.

Eur J Cancer. 2006 May;42(8):1057-61. Epub 2006 Apr 18.

PMID:
16624551
44.

The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1.

Berno V, Porrini D, Castiglioni F, Campiglio M, Casalini P, Pupa SM, Balsari A, Ménard S, Tagliabue E.

Endocr Relat Cancer. 2005 Jun;12(2):393-406.

45.

Role of HER2/neu in tumor progression and therapy.

Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E.

Cell Mol Life Sci. 2004 Dec;61(23):2965-78. Review.

PMID:
15583858
46.

Role of HER receptors family in development and differentiation.

Casalini P, Iorio MV, Galmozzi E, Ménard S.

J Cell Physiol. 2004 Sep;200(3):343-50. Review.

PMID:
15254961
47.

HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA.

Galmozzi E, Casalini P, Iorio MV, Casati B, Olgiati C, Ménard S.

J Cell Physiol. 2004 Jul;200(1):82-8.

PMID:
15137060
48.

Immunological and pathobiological roles of fibulin-1 in breast cancer.

Pupa SM, Argraves WS, Forti S, Casalini P, Berno V, Agresti R, Aiello P, Invernizzi A, Baldassari P, Twal WO, Mortarini R, Anichini A, Ménard S.

Oncogene. 2004 Mar 18;23(12):2153-60. Erratum in: Oncogene. 2004 Aug 19;23(37):6325. Argraves SW [corrected to Argraves WS].

PMID:
14691454
49.

Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.

Ménard S, Casalini P, Tagliabue E, Pupa SM, Balsari A.

J Natl Cancer Inst. 2003 Jun 18;95(12):917-8; author reply 918-9. No abstract available.

PMID:
12813176
50.

Role of hormonal risk factors in HER2-positive breast carcinomas.

Balsari A, Casalini P, Bufalino R, Berrino F, Ménard S.

Br J Cancer. 2003 Apr 7;88(7):1032-4.

Supplemental Content

Loading ...
Support Center